Preprint
Article

Spaceflight and Microgravity-dependent Alteration of Mast cell Population and Protease Expression in Digestive Organs of Mongolian Gerbils

Submitted:

10 August 2023

Posted:

11 August 2023

You are already at the latest version

A peer-reviewed article of this preprint also exists.

Abstract
Abstract: Mast cell (MC) specific proteases are of particular interest for space biology and medicine due to their biological activity in regulating targets of a specific tissue microenvironment. MC tryptase and chymase obtain the ability to remodel connective tissue through direct and indirect mechanisms. Yet, MC specific protease expression under space flight conditions has not been adequately investigated. Using immunohistochemical stainings, we analyzed in this study the protease profile of the jejunal, gastric and hepatic MC populations in three groups of Mongolian gerbils - vivarium control, synchronous experiment, and 12-day orbital flight on the Foton-M3 spacecraft, - and in two groups - vivarium control and anti-orthostatic suspension - included in the experiment simulating effects of weightlessness in the ground-based conditions. After a space flight, there was a decreased number of MCs in the studied organs combined with an increased proportion of chymase-positive MCs and MCs with a simultaneous content of tryptase and chymase; the secretion of specific proteases into the extracellular matrix increased. These changes in the expression of proteases were observed both in the mucosal and connective tissue MC subpopulations of the stomach and jejunum. Notably, the relative content of tryptase-positive MCs in the studied organs of the digestive system decreased. Space flight conditions simulated in the synchronous experiment caused no similar significant changes in the protease profile of MC populations. The space flight conditions resulted in an increased chymase expression combined with a decreased total number of protease-positive MCs apparently due to participating in the processes of extracellular matrix remodeling and regulating the state of the cardiovascular system.
Keywords: 
;  ;  ;  ;  ;  

1. Introduction

The space industry’s scientific and technical infrastructure is currently improving, enabling an increase in the length of time a human can spend in the circumstances of orbital flight [1]. Today’s understanding of life is largely framed and well-studied in terms of how it has evolved and persisted under the gravitational pull of the Earth (1G). Earth’s gravity field becomes weaker inversely with the square of the distance from the planet (also known as inverse square law), so the pull of gravity in Low Earth Orbit (LEO) where ISS orbits is slightly less than on the Earth’s surface [2]. Additionally, astronauts during their stay in space face various health issues largely due to the change in diet, radiation (which may result in genetic mutations and cancer), stress, etc [3,4]. The ability of spaceflights to affect human immune cells and as a result, the orchestration of immune responses have always been the focus of interest and attention. In line with this, the cytotoxic activity of NK cells obtained from astronauts who spent a long time on ISS was shown to be reduced notably when compared to normal ground-based counterparts or preflight samples upon being exposed to a panel of tumor cell lines [5]. One of the innate immune cell types is Mast cells (MCs), which we already comprehensively reviewed their biology [6]. MCs develop from CD34+/CD117+ progenitors that after being liberated from bone marrow, find their way in circulation according to a finely-tuned chemokine and integrin-based trafficking to different tissues including gastrointestinal tissues [7,8,9,10]. In humans, MCs classically are classified according to their content of proteases in two subsets namely MCT (expressing tryptase) and MCTC (expressing tryptase and chymase) [11]. The data obtained recently using molecular techniques evidence a pronounced polyfunctionality of MC proteases about the state of the extracellular matrix (ECM), target cells, and mechanisms of the tissue microenvironment remodeling [12,13,14,15,16,17,18,19]. Considering the role and significance of MCs in not only allergic events but in non-allergic pathologies, their biology deserves to be studied in microgravity to have a better insight into their orchestrated immune network and crosstalk with other components of the immune system. However, to date, there is limited research in this area. The present study aimed to investigate the MC protease profile of the stomach, jejunum, and liver in Mongolian gerbils under 12-day space flight conditions and simulated the physiological effects of weightlessness in ground-based conditions.

2. Results

When studying gastric micropreparations of experimental animals, it was found that the animals of the vivarium group were characterized by the prevailing tryptase-positive MC population in the mucous membrane, while sporadically chymase expression was detected. MCs expressing chymase predominated in the MC connective tissue subpopulation localized in the submucosa and muscle membranes. When examining the submucosa, a greater number of chymase-positive MCs were detected; their number was only slightly less than the number of tryptase-positive MCs compared to the level detected in the mucosa (Table 1, Figure 1).
This was also supported by the MC protease profile evidencing a higher content of MCs with the expression of chymase exclusively, as well as MCs with the expression of both proteases simultaneously in the connective tissue of the submucosal, muscular, and serous membranes (Table 2, Figure 1).
A number of MCs was detected in the jejunum of animals from the vivarium group using immunohistochemical tryptase identification. Tryptase-positive MCs formed groups and also happened to be located singly (Figure 2). In the mucosa, they were more often located in the intercryptal stroma. A few MCs were localized at the border of the mucosa and submucosa. In the MC cytoplasm, tryptase-positive granules were well visualized, they had clarification in the central part. There were tryptase-containing granules located at a distance from the MC, this being a reflection of their secretory activity. In addition, different gradations of MC staining during the immunohistochemical tryptase detection came under notice, the fact, apparently, to a certain extent, indicating a different content of this enzyme in MCs. Detection of MC protease profile in the population demonstrated a significant predominance of tryptase-containing cells over chymase-expressing ones. The number of tryptase-positive MCs was prevalent both in the mucosa and in other membranes of the jejunum (Figure 2). Notably, as the analysis of the protease profile of the subpopulation demonstrated, the relative expression of chymase was slightly higher in the lamina propria of the jejunal mucous membrane compared to the MC connective tissue subpopulation.
Further, MCs were predominantly localized in the region of the base of the villi and the muscularis mucosal plate. MCs in the region of the muscular and adventitious membranes were the least likely to express chymase, it was present in single cells.
In the liver of animals, tryptase-positive MCs accounted for an insignificant number, localized mainly within the connective tissue of the portal tracts and central veins, while chymase-positive MCs practically failed to be detected (Table 1, Figure 3).
In the synchronous experiment, MC protease profile of the stomach and liver walls changed insignificantly. The number of tryptase-positive and chymase-containing MCs differed insignificantly compared to the parameters manifested by Mongolian gerbils from the vivarium control group (Figure 1 and Figure 3). After the synchronous experiment, chymase expression increased in MCs located in the submucosa of the jejunum (Table 1, Figure 2). Among the connective tissue MCs, there was a shift in the protease profile towards an increased chymase expression (Table 2).
Figure 1. Gastric mast cells of Mongolian gerbils. Experimental groups: (AE) vivarium control, (F,G) synchronous experiment, (H,I) space flight, (JL) antiorthostatic suspension. Notes: (A) Localization of tryptase-positive MCs at different levels in the lamina propria. (BC) chymase-positive (B) and tryptase-positive (C) MCs in the submucosa. (D) Attachment of MCs to the gastric proper glands of the connective tissue subpopulation, immunohistochemical staining of mast cell tryptase. (E) Secretion of chymase to submucosal fibroblast (presumably). (F) Localization of tryptase-positive mast cells in the gastric mucosa. (G) A submucosal mast cell containing both tryptase and chymase, distributed predominantly along the periphery of the secretory granules. (H) The appearance of chymase-positive MCs in the area of the proper glands of the gastric mucosa. (I) Two distinct MC phenotypes in the submucosa, with visualized chymase secretion into the extracellular matrix. (J) A mucosal mast cell filled with large tryptase-positive granules, with evident secretion into the intercellular substance. (K,L) Chymase-positive MCs in the perivascular region of the submucosal muscular artery (K) and mucosal intrinsic plasty (L). Scale: (A) 50 µm, the rest—10 µm.
Figure 1. Gastric mast cells of Mongolian gerbils. Experimental groups: (AE) vivarium control, (F,G) synchronous experiment, (H,I) space flight, (JL) antiorthostatic suspension. Notes: (A) Localization of tryptase-positive MCs at different levels in the lamina propria. (BC) chymase-positive (B) and tryptase-positive (C) MCs in the submucosa. (D) Attachment of MCs to the gastric proper glands of the connective tissue subpopulation, immunohistochemical staining of mast cell tryptase. (E) Secretion of chymase to submucosal fibroblast (presumably). (F) Localization of tryptase-positive mast cells in the gastric mucosa. (G) A submucosal mast cell containing both tryptase and chymase, distributed predominantly along the periphery of the secretory granules. (H) The appearance of chymase-positive MCs in the area of the proper glands of the gastric mucosa. (I) Two distinct MC phenotypes in the submucosa, with visualized chymase secretion into the extracellular matrix. (J) A mucosal mast cell filled with large tryptase-positive granules, with evident secretion into the intercellular substance. (K,L) Chymase-positive MCs in the perivascular region of the submucosal muscular artery (K) and mucosal intrinsic plasty (L). Scale: (A) 50 µm, the rest—10 µm.
Preprints 82122 g001
Figure 2. Jejunal mast cells of Mongolian gerbils. Experimental groups: (AE) vivarium control, (FH) synchronous experiment, (IO) space flight, (P,Q) antiorthostatic suspension. Notes: (A) Distribution of tryptase-positive MCs in all structures of the jejunum, chymase-positive MCs are absent in the mucosa. (B) Grouping of tryptase-positive MCs. (C) Distribution of tryptase along the periphery of contacting mast cell granules. (D) A mast cell is filled with tryptase-positive granules. Part of them are transported to the extracellular matrix (arrowed). (E) Localization of chymase in large submucosal MC granules, part of them are secreted (arrowed). (F) Mucosal mast cells contacting with immunocompetent cells (arrowed) and smooth myocytes of the muscularis lamina (double arrowed). (G) Chymase-positive cells in the muscle layer. (H) Chymase-positive MCs at the base of the mucosal villus with signs of degranulation. (I) Severe degranulation of tryptase-positive MC granules at the mucosal-submucosal interface. (J) Migration of tryptase-positive MCs in the stroma of the jejunal villus. (K) Different mechanisms of tryptase degranulation into the extracellular matrix (arrowed). (L) Chymase-positive MCs in the muscle layer. (M) Increase in the number of chymase-positive MCs in the mucosa. (N,O) MCs with simultaneous tryptase and chymase expression. (P) Tryptase-positive mucosal MCs with signs of degranulation. (Q) Active secretion of chymase-positive granules into a specific mucosal tissue microenvironment. Scale: (A) 100 µm, the rest—10 µm.
Figure 2. Jejunal mast cells of Mongolian gerbils. Experimental groups: (AE) vivarium control, (FH) synchronous experiment, (IO) space flight, (P,Q) antiorthostatic suspension. Notes: (A) Distribution of tryptase-positive MCs in all structures of the jejunum, chymase-positive MCs are absent in the mucosa. (B) Grouping of tryptase-positive MCs. (C) Distribution of tryptase along the periphery of contacting mast cell granules. (D) A mast cell is filled with tryptase-positive granules. Part of them are transported to the extracellular matrix (arrowed). (E) Localization of chymase in large submucosal MC granules, part of them are secreted (arrowed). (F) Mucosal mast cells contacting with immunocompetent cells (arrowed) and smooth myocytes of the muscularis lamina (double arrowed). (G) Chymase-positive cells in the muscle layer. (H) Chymase-positive MCs at the base of the mucosal villus with signs of degranulation. (I) Severe degranulation of tryptase-positive MC granules at the mucosal-submucosal interface. (J) Migration of tryptase-positive MCs in the stroma of the jejunal villus. (K) Different mechanisms of tryptase degranulation into the extracellular matrix (arrowed). (L) Chymase-positive MCs in the muscle layer. (M) Increase in the number of chymase-positive MCs in the mucosa. (N,O) MCs with simultaneous tryptase and chymase expression. (P) Tryptase-positive mucosal MCs with signs of degranulation. (Q) Active secretion of chymase-positive granules into a specific mucosal tissue microenvironment. Scale: (A) 100 µm, the rest—10 µm.
Preprints 82122 g002
After the space flight, there was a decreased number of tryptase-positive MCs in the lamina propria of the mucous membrane in the gastric micropreparations (Table 1). However, concurrently, there was a significantly increased number of chymase-positive MCs in the mucosa, both in absolute and relative values, compared to the number of MCs detected in the synchronous experiment (Table 1 and Table 2).
Changes in the protease profile reflected an increased chymase expression after spaceflight, especially in the mucosa (Figure 1). It should be emphasized that there was an increase in the number of MCs expressing exclusively chymase and in the number of MCs expressing both tryptase and chymase simultaneously (Table 2).
As supported by the analysis of the biomaterial performed after the immunohistochemical tryptase detection, there was a decrease in the population of MCs in the wall of the jejunum. Quantitative calculations demonstrated a decreased volume of tryptase-positive MCs in the jejunal stroma of Mongolian gerbils. This was found in both mucosal and submucosal subpopulations. Tryptase-positive MCs sometimes formed clusters in which they grouped and connected (Figure 2). On the part of tryptase-containing MCs, a pronounced intensification of degranulation was detected (Figure 2). In particular, exocytosis of secretory granules was activated both in the mucous membrane and in other membranes of the jejunum. Concurrently, tryptase-positive granules were found at a sufficient distance from MCs, being freely localized in the intercryptal stroma of the mucosa. Evidently, after the space flight, the effects of intense degranulation could lead to a decreased volume of the MC cytoplasm, reflecting the entry of biologically active substances into the stroma. Occasionally, tryptase-positive granules were only one row in the cytoplasm, located perinuclearly. Tryptase-containing MCs were also detected in the stroma of the villi. After the space flight, there was an increased representation of chymase-containing MCs both in the lamina propria of the mucous membrane and other membranes of the jejunum (Table 1). The number of MCs containing both proteases or exclusively chymase increased significantly compared with the indices of animals from the groups of synchronous experiment and vivarium control, primarily within the submucosal and muscular membranes.
In the liver of animals from the flight group, the representation of chymase-containing MCs increased (Table 1, Figure 3). This was due to both - an increased representation of chymase-positive MCs and MCs with simultaneous expression of chymase and tryptase (Table 2). An increased level of chymase production should be considered an important compensatory mechanism for organ adaptation to space flight conditions.
After antiorthostatic suspension, the number of chymase-containing MCs in the gastric mucosa increased compared to the parameters detected in the animals from the vivarium group (Table 1). The protease profile detection demonstrated that chymase expression increased both in the mucosal and regular MC subpopulations (Table 2, Figure 1). This was especially noticeable in the MCs of the mucosal lamina propria. Notably, the absolute amount of tryptase-containing MCs, which were well identified in the stomach wall, practically had no changes compared to the parameters of animals from the vivarium group (Table 1).
Regarding the jejunal mucosa, one can only say about a forming trend towards a decrease in the number and some increase in the submucosa and muscular membranes of tryptase-positive MCs. There were often observed patterns of release of tryptase-containing granules (Figure 2). Attention was also drawn to the increased level of chymase-positive MCs both in the mucosa and submucosa.
Figure 3. Hepatic mast cells of Mongolian gerbils. Experimental groups: (AD) vivarium control, (EH) space flight, (IK) antiorthostatic suspension. Techniques: (A,E,I) staining with toluidine blue, (B,F,J) determination of chloroacetate esterase activity, (C,D,G,H,K) immunohistochemical staining of specific MC proteases. Notes: (AD) Mast cells in various morphofunctional states in the stroma of portal triads. The contact formation of MCs with each other is typical. (E) Degranulation of MCs in the liver lobule. (F). MCs in the stroma of the portal tract, close contact with pericyte (arrowed). (G) A chymase-positive MC in the liver lobule. (H) Chymase- and tryptase-positive MCs in the region of the portal tract. (I) High content of mast cells in the periportal region, active secretion of biosynthetic products into the extracellular matrix (arrowed). (J) MCs of the portal tract in a state of active secretion (arrowed). (K) Mast cells with diverse protease expression in the portal tract region. Scale: 10 µm.
Figure 3. Hepatic mast cells of Mongolian gerbils. Experimental groups: (AD) vivarium control, (EH) space flight, (IK) antiorthostatic suspension. Techniques: (A,E,I) staining with toluidine blue, (B,F,J) determination of chloroacetate esterase activity, (C,D,G,H,K) immunohistochemical staining of specific MC proteases. Notes: (AD) Mast cells in various morphofunctional states in the stroma of portal triads. The contact formation of MCs with each other is typical. (E) Degranulation of MCs in the liver lobule. (F). MCs in the stroma of the portal tract, close contact with pericyte (arrowed). (G) A chymase-positive MC in the liver lobule. (H) Chymase- and tryptase-positive MCs in the region of the portal tract. (I) High content of mast cells in the periportal region, active secretion of biosynthetic products into the extracellular matrix (arrowed). (J) MCs of the portal tract in a state of active secretion (arrowed). (K) Mast cells with diverse protease expression in the portal tract region. Scale: 10 µm.
Preprints 82122 g003
As the study of the protease profile of the MC population demonstrated, there was an increased chymase expression in MCs. Interestingly, MCs with chymase expression, as well as MCs with both proteases simultaneously, were detected with greater frequency. Accordingly, the number of MCs expressing tryptase only significantly decreased. There were found patterns of exocytosis of chymase-positive granules that were not so pronounced in animals from the vivarium control group.
In the liver, the conditions of antiorthostatic suspension resulted in the activation of chymase expression, which manifested itself both in chymase-containing MCs and by a significantly increasing number of MCs with simultaneous expression of tryptase and chymase (Figure 3). This coincided with the increased total amount of MCs in the liver, primarily in the region of portal triads, which were detected by histochemical staining with toluidine blue and determining the chloroacetate esterase activity (Figure 3). However, the chymase expression in MCs increased more significantly after the space flight compared to the findings obtained in the simulated experiment (Table 1).

3. Discussion

As known, MCs contain the largest range of peptidases both quantitatively and qualitatively if compared with other cells of the immune system [19,20,21]. MC proteases are localized in the cytoplasm mainly in granules that are packaged by the serglycin-glycosaminoglycan complex [14,15,16,17,22,23].
Chymase has the potential to convert angiotensin I to angiotensin II, regardless of the angiotensin-converting enzyme, which, of course, is of particular significance for blood pressure regulation [24]. Angiotensin II increases the expression of vascular endothelial growth factor (VEGF) by various cells. In spaceflight, an increased chymase expression can represent a certain compensation for a decrease in tryptase biogenesis, maintaining the hypersecretory state of the stomach in microgravity. Chymase can hydrolytically inactivate peptides such as bradykinin [25], as well as some neuropeptides, including substance P (SP) and vasoactive intestinal peptide (VIP) [26]. This property allows chymase, unlike tryptase, to inactivate certain bronchoconstrictors that may limit MC degranulation. Chymase is involved in inflammation modulation by affecting the activation of a number of interleukins [27]. It also has the potential to cleave allergens and specific blood proteins [28], hepatocyte growth factor [29], and endogenous immune proteins, including interleukin-6 and interleukin-13 [30]. In terms of tissue remodeling, chymase effects are crucial in relation to the local activation of matrix metalloproteinases (MMPs) - 1 and 3, followed by degradation of several elements of the extracellular matrix [31]. The presence of heparin resulted in a significant increase in the rate at which chymase activated some MMPs, both by accelerating the cleavage of their precursors and by preventing their further degradation. In particular, chymase may activate MMP-1 directly by cleaving leucine and threonine without any intermediates [32].
The detection of chymase-positive MCs in the digestive organs of Mongolian gerbils significantly expanded the interpretation of their potential activity in the organ in response to external exposure. Even though their content in vivarium animals was insignificant, there was a considerable increase in chymase expression after space flight and, to a lesser extent, after the simulated physiological effects of weightlessness, the fact attracting attention. This supported the critical role of MC-produced chymase in adaption to space flight factors, in particular weightlessness.
Tryptase has a wider range of bioeffects that affect the formation of the cellular and extracellular phenotype of an organ-specific tissue microenvironment under certain environmental conditions [12,33].
This largely is due to the expression of its main receptor protease-activated receptor-2 (PAR-2) on different immune and non-immune cells (including endothelial cells [34], spermatozoa [35], and tumor cells [18]). The experimental data obtained over the past few years on the role of tryptase and chymase allow for considering these proteases as promising objects of study in laboratory experiments and in search for new targets for the pharmacological correction of various diseases [13,36,37,38].
The effects of tryptase secretion can be either local, limited to the effect on nearby cells and structures, or more widespread, involving specific organs (for example, in asthmatic bronchospasm), up to generalization, as in systemic mastocytosis or anaphylaxis [39]. It has been found that the intrinsic products of MC biosynthesis can lead to further enhancement of their degranulation by a positive feedback mechanism, potentiating the release of mediators. As demonstrated, an autocrine mechanism of the tryptase activating effect on mast cell degranulation can also extend to eosinophilic granulocytes [39]. Perhaps, it was that particular mechanism that led to significant consumption of mast cell tryptase during the first period of laboratory animals’ stay in weightlessness; this resulted in the depletion of physiological resources, which was observed after space flight.
The cellular and tissue effects of tryptase can be divided into pro-inflammatory and anti-inflammatory [40]. However, in most cases, tryptase is the initiator of inflammatory reactions accompanied by increased capillary permeability and intensive granulocyte recruitment [41]. Tryptase is involved in angiogenesis, degradation of fibrous and amorphous components of the extracellular matrix of connective tissue, and release of growth factors, which can be the results of tryptase-mediated activation of MMPs mainly MMP-2 and MMP-9 [18]. These endopeptidases play a crucial role in the degradation of structural elements of ECM such as collagen [42,43].
Given the aforementioned aspects of the importance of MC proteases and the fact that cancer and metastasis are among the previously researched effects of prolonged human spaceflights [44,45], MCs may be involved through tissue accumulation, producing high levels of proteases, leading to dysregulation of MMP production, which ultimately results in excessive damage to the ECM, the liberation of tumor cells, and the progression of metastasis.
Several mechanisms of tryptase effect promoting the growth and differentiation of new blood vessels are discussed in the literature [39,46]. Probably, the intense secretion of tryptase during the first period of orbital flight leads to additional vessel formation in the gastric and intestinal mucous membranes. This fact, among other things, can explain developing mucosal edema, and also be one of the reasons for implementing the hemodynamic mechanism of the stomach hypersecretory state in microgravity [47]. Notably, generalization of this effect of tryptase may also be provided, since this protease leads to a potentiation of histamine release. Histamine, in turn, stimulates a further increase in tryptase secretion, promoting signal propagation from one group of activated MCs to others [48]. Tryptase also inactivates procoagulant proteins, in particular, kininogen and fibrinogen [49]. The increased vascular permeability under the tryptase effect occurs indirectly by increasing the kinin formation. In addition, tryptase induces the expression of interleukin-1 and interleukin-8 from endothelial cells, which can be combined with an increased synthesis of the Intercellular adhesion molecule 1 (ICAM-1) and an increased leukocyte tissue infiltration, as well as the further development of tissue edema in a specific area [39]. This effect is also prolonged due to tryptase’s ability to destroy neuropeptides, including VIP.
Notably, tryptase deficiency in the wall of the stomach and jejunum, developing by the 12th day of space flight, can also result in a deficiency in the mitogenic effect of tryptase on smooth myocytes. This fact, further, can be the cause of thinning of the smooth muscle layer in the wall of the hollow digestive organs and affects the digestive tube motor activity [50].

4. Materials and methods

4.1. Experimental design

The units of analysis were mast cells of the stomach, jejunum, and liver of male Mongolian gerbils (Meriones unguiculatus) divided into several groups. The flight experiment group, implemented within the Foton-M3 12-day orbital flight research project, consisted of 12 animals. The group of the ground-based synchronous experiment included 11 Mongolian gerbils, which stayed for 12 days in the prototype of the flight equipment “Kontur-L” to simulate certain characteristics of space flight circumstances. The third group included 12 vivarium animals. The decapitation of the animals from the flight experiment group was carried out 21 hours after the landing. Specific physiological effects of weightlessness were simulated using antiorthostatic suspension according to the Ilyin-Novikov technique interpreted by Moray-Holton [51]. This experiment included two groups of animals: of these, eight animals were subjected to 12-day antiorthostatic suspension, and another 8 animals served as a vivarium group. All stomach, jejunum, and liver tissues were obtained from the Institute of Medical and Biological Problems (IMBP), the Russian Academy of Sciences (Moscow), in compliance with all the requirements for the human treatment of animals, in accordance with the decision of the Commission on Biomedical Ethics of the IBMP (Protocol No. 206 dated 07.10.2007).

4.2. Histoprocessing

Fragments of the fundic zone of the stomach, the middle of the left lobe of the liver, and the jejunum were embedded in paraffin according to the standard sample preparation procedure after fixing them for 24–48 h in 10% neutral formalin at room temperature [52,53]. Histological sections with 2 μm thickness were prepared for immunomorphological analysis using an Accu-Cut® SRM™ 200 semi-automatic rotary microtome (Sakura Finetek Europe B.V.). In the stomach and jejunum, there was performed a separate study of the mucosal and connective tissue subpopulations of MCs localized in the mucosa and the interstitium of other membranes, respectively. In the liver, MCs were represented only by a connective tissue subpopulation.

4.3. Tissue Probe Staining

Immunohistochemical staining was used to identify MC proteases. Single and multiple immunofluorescence labeling was performed according to standard protocols [52]. Concurrently, according to the standard immunolabeling protocol [52], tryptase was detected using mouse monoclonal antibodies (Table 3). Homologous mouse immunoglobulins were blocked during pre-incubation of sections with unconjugated Fab fragments (goat anti-mouse IgG, Jackson ImmunoResearh, #115-007-003, 1:13, Table 4). Rabbit polyclonal antibodies conjugated with biotin were used to stain chymase MCs (Table 3). The list of secondary antibodies and other reagents used in this study is presented in Table 4. A kit with 3.3’-diaminobenzidine as a substrate was used to detect secondary antibodies conjugated with HRP (Table 4). Before the preparation embedding, the nuclei were stained with Mayer’s hematoxylin.
Protease colocalization in MCs was determined by fluorescence microscopy after incubation with primary antibodies diluted 1:500 to chymase and 1:2000 to tryptase overnight at +4 °C. Then, using streptavidin (Streptavidin AlexaFluor 488, # S11223), biotin-bound anti-chymase antibodies were identified and visualized using an appropriate filter. Cy3-conjugated secondary antibodies (CyTM3-conjugated AffinPure Goat Anti Mouse IgG, #115-165-166, 10 mg/ml PBS) were used to detect anti-tryptase primary antibodies. The nuclei were counterstained with DAPI and the sections were mounted in Vectashield temporary mounting medium (Table 4). The staining for fluorescence microscopy was performed according to the standard protocol technique [52].

4.4. Image acquisition

Stained tissues were studied using a hardware-software complex based on a ZEISS Axio Imager.A2 research microscope (Carl Zeiss Microscopy, Germany) with a documentation system. The ZEN 2.3 software (blue edition, Carl Zeiss, Germany) was used to analyze the obtained images using a monochrome Camera Axiocam 503 mono (for fluorescence microscopy) and a Camera Axiocam 506 color (for bright-field microscopy). MCs were calculated in fields of vision measured 700 × 500 μm, obtained using a lens 20×. The studied areas had no intersections with each other on the micropreparations. A minimum of 15 fields of vision were investigated in each section. When calculating the parameters of MC population features, both absolute and relative values were used, calculated as a percentage of the total number.

4.5. Statistical analysis

Statistical analysis was performed using the SPSS software package (V. 13.0, IBM, Unites States). The results are presented as mean (M) ± m (standard error of the mean). To assess the significance of the differences between the two groups, Student’s t-test or Mann–Whitney U test in the case of a nonparametric distribution was used.

5. Conclusions

Thus, the high content of tryptase and chymase in MCs provides their active participation in coordinating the integrative-metabolic state of the connective tissue, including microgravity during space flight [54]. After the orbital flight and the ground-based simulated physiological effects of weightlessness, the ratio of proteases in mast cells of the digestive system of Mongolian gerbils changed due to increased chymase expression. This evidences the close involvement of MCs located in the organs of the gastrointestinal tract in the processes of adaptation to space flight factors, including the immune and stromal landscapes of the specific tissue microenvironment of the studied digestive organs. Modification of the MC protease profile has a direct effect on the adaptive remodeling of the extracellular matrix of connective tissue under altered gravity.

Author Contributions

Data curation, D.A. and A.K.; Formal analysis, D.E.K, V.S. and A.B.; Investigation, D.A. and A.B.; Methodology, A.V., V.S. and I.B.; Project administration, A.K. and M.T.; Writing—original draft, D.A. and A.B.; Writing review and editing, D.A. and I.B.; contributed to the preparation of the manuscript, edited, and added inputs to the final version, DEAK. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Committee on Biomedical Ethics of the Institute of Biomedical Problems, Russian Academy of Sciences (protocol № 206 dated 07.10.2007).

Informed Consent Statement

Not applicable.

Acknowledgments

This publication has been supported by RUDN University project № 210500-2-000 «Molecular mechanisms of mast cell participation in the formation of the immune and stromal landscape of a specific tissue microenvironment in normal and pathological conditions».

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

ISS International Space Station
MC Mast cell
LEO Low Earth Orbit
ECM Extracellular matrix
PAR-2 Protease-activated receptor-2
VEGF Vascular endothelial growth factor
VIP Vasoactive intestinal peptide
SP Substance P
ICAM-1 Intercellular adhesion molecule 1
MMPs Metalloproteinases

References

  1. Loued-Khenissi, L.; Pfeiffer, C.; Saxena, R.; Adarsh, S.; Scaramuzza, D. Microgravity induces overconfidence in perceptual decision-making. Sci Rep 2023, 13, 9727. [Google Scholar] [CrossRef] [PubMed]
  2. Kandarpa, K.; Schneider, V.; Ganapathy, K. Human health during space travel: An overview. Neurol India 2019, 67, S176–S181. [Google Scholar] [CrossRef]
  3. Chancellor, J.C.; Scott, G.B.; Sutton, J.P. Space Radiation: The Number One Risk to Astronaut Health beyond Low Earth Orbit. Life 2014, 4, 491–510. [Google Scholar] [CrossRef] [PubMed]
  4. Sonnenfeld, G. Space flight, microgravity, stress, and immune responses. Adv Space Res 1999, 23, 1945–1953. [Google Scholar] [CrossRef]
  5. Bigley, A.B.; Agha, N.H.; Baker, F.L.; Spielmann, G.; Kunz, H.E.; Mylabathula, P.L.; Rooney, B.V.; Laughlin, M.S.; Mehta, S.K.; Pierson, D.L.; et al. NK cell function is impaired during long-duration spaceflight. J Appl Physiol (1985) 2019, 126, 842–853. [Google Scholar] [CrossRef] [PubMed]
  6. Elieh Ali Komi, D.; Wohrl, S.; Bielory, L. Mast Cell Biology at Molecular Level: A Comprehensive Review. Clin Rev Allergy Immunol 2020, 58, 342–365. [Google Scholar] [CrossRef] [PubMed]
  7. Elieh Ali Komi, D.; Bjermer, L. Mast Cell-Mediated Orchestration of the Immune Responses in Human Allergic Asthma: Current Insights. Clin Rev Allergy Immunol 2019, 56, 234–247. [Google Scholar] [CrossRef]
  8. Elieh Ali Komi, D.; Grauwet, K. Role of Mast Cells in Regulation of T Cell Responses in Experimental and Clinical Settings. Clin Rev Allergy Immunol 2018, 54, 432–445. [Google Scholar] [CrossRef]
  9. Elieh Ali Komi, D.; Shafaghat, F.; Kovanen, P.T.; Meri, S. Mast cells and complement system: Ancient interactions between components of innate immunity. Allergy 2020, 75, 2818–2828. [Google Scholar] [CrossRef]
  10. Komi, D.E.A.; Mortaz, E.; Amani, S.; Tiotiu, A.; Folkerts, G.; Adcock, I.M. The Role of Mast Cells in IgE-Independent Lung Diseases. Clin Rev Allergy Immunol 2020, 58, 377–387. [Google Scholar] [CrossRef]
  11. Elieh Ali Komi, D.; Ribatti, D. Mast cell-mediated mechanistic pathways in organ transplantation. Eur J Pharmacol 2019, 857, 172458. [Google Scholar] [CrossRef]
  12. Hernandez-Hernandez, L.; Sanz, C.; Garcia-Solaesa, V.; Padron, J.; Garcia-Sanchez, A.; Davila, I.; Isidoro-Garcia, M.; Lorente, F. Tryptase: Genetic and functional considerations. Allergol Immunopathol (Madr) 2012, 40, 385–389. [Google Scholar] [CrossRef]
  13. Caughey, G.H. Mast cell proteases as pharmacological targets. Eur J Pharmacol 2016, 778, 44–55. [Google Scholar] [CrossRef]
  14. Atiakshin, D.; Buchwalow, I.; Samoilova, V.; Tiemann, M. Tryptase as a polyfunctional component of mast cells. Histochem Cell Biol 2018, 149, 461–477. [Google Scholar] [CrossRef] [PubMed]
  15. Atiakshin, D.; Buchwalow, I.; Tiemann, M. Mast cell chymase: Morphofunctional characteristics. Histochem Cell Biol 2019, 152, 253–269. [Google Scholar] [CrossRef] [PubMed]
  16. Atiakshin, D.; Kostin, A.; Trotsenko, I.; Shishkina, V.; Tiemann, M.; Buchwalow, I. Carboxypeptidase A3 in the structure of the protease phenotype of mast cells: Cytophysiological aspects. RUDN Journal of Medicine 2022, 26, 9–33. [Google Scholar] [CrossRef]
  17. Atiakshin, D.; Kostin, A.; Trotsenko, I.; Samoilova, V.; Buchwalow, I.; Tiemann, M. Carboxypeptidase A3-A Key Component of the Protease Phenotype of Mast Cells. Cells 2022, 11, 570. [Google Scholar] [CrossRef]
  18. Komi, D.E.A.; Redegeld, F.A. Role of Mast Cells in Shaping the Tumor Microenvironment. Clin Rev Allergy Immunol 2020, 58, 313–325. [Google Scholar] [CrossRef]
  19. Hellman, L.; Akula, S.; Fu, Z.; Wernersson, S. Mast Cell and Basophil Granule Proteases—In Vivo Targets and Function. Front Immunol 2022, 13, 918305. [Google Scholar] [CrossRef]
  20. Trivedi, N.N.; Caughey, G.H. Mast cell peptidases: Chameleons of innate immunity and host defense. Am J Respir Cell Mol Biol 2010, 42, 257–267. [Google Scholar] [CrossRef]
  21. Elieh Ali Komi, D.; Shafaghat, F.; Christian, M. Crosstalk Between Mast Cells and Adipocytes in Physiologic and Pathologic Conditions. Clin Rev Allergy Immunol 2020, 58, 388–400. [Google Scholar] [CrossRef]
  22. Ronnberg, E.; Melo, F.R.; Pejler, G. Mast cell proteoglycans. J Histochem Cytochem 2012, 60, 950–962. [Google Scholar] [CrossRef] [PubMed]
  23. Elieh Ali Komi, D.; Jalili, A. The emerging role of mast cells in skin cancers: Involved cellular and molecular mechanisms. Int J Dermatol 2022, 61, 792–803. [Google Scholar] [CrossRef]
  24. Wintroub, B.U.; Kaempfer, C.E.; Schechter, N.M.; Proud, D. A human lung mast cell chymotrypsin-like enzyme. Identification and partial characterization. J Clin Invest 1986, 77, 196–201. [Google Scholar] [CrossRef] [PubMed]
  25. Reilly, C.F.; Schechter, N.B.; Travis, J. Inactivation of bradykinin and kallidin by cathepsin G and mast cell chymase. Biochem Biophys Res Commun 1985, 127, 443–449. [Google Scholar] [CrossRef] [PubMed]
  26. Franconi, G.M.; Graf, P.D.; Lazarus, S.C.; Nadel, J.A.; Caughey, G.H. Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. J Pharmacol Exp Ther 1989, 248, 947–951. [Google Scholar]
  27. Mizutani, H.; Schechter, N.; Lazarus, G.; Black, R.A.; Kupper, T.S. Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med 1991, 174, 821–825. [Google Scholar] [CrossRef]
  28. Raymond, W.W.; Ruggles, S.W.; Craik, C.S.; Caughey, G.H. Albumin is a substrate of human chymase. Prediction by combinatorial peptide screening and development of a selective inhibitor based on the albumin cleavage site. J Biol Chem 2003, 278, 34517–34524. [Google Scholar] [CrossRef]
  29. Raymond, W.W.; Cruz, A.C.; Caughey, G.H. Mast cell and neutrophil peptidases attack an inactivation segment in hepatocyte growth factor to generate NK4-like antagonists. J Biol Chem 2006, 281, 1489–1494. [Google Scholar] [CrossRef]
  30. Zhao, W.; Oskeritzian, C.A.; Pozez, A.L.; Schwartz, L.B. Cytokine production by skin-derived mast cells: Endogenous proteases are responsible for degradation of cytokines. J Immunol 2005, 175, 2635–2642. [Google Scholar] [CrossRef]
  31. Lees, M.; Taylor, D.J.; Woolley, D.E. Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of gelatinases A and B. Eur J Biochem 1994, 223, 171–177. [Google Scholar] [CrossRef] [PubMed]
  32. Saarinen, J.; Kalkkinen, N.; Welgus, H.G.; Kovanen, P.T. Activation of human interstitial procollagenase through direct cleavage of the Leu83-Thr84 bond by mast cell chymase. J Biol Chem 1994, 269, 18134–18140. [Google Scholar] [CrossRef] [PubMed]
  33. Mulloy, B.; Lever, R.; Page, C.P. Mast cell glycosaminoglycans. Glycoconj J 2017, 34, 351–361. [Google Scholar] [CrossRef] [PubMed]
  34. Morais, C.; Rajandram, R.; Blakeney, J.S.; Iyer, A.; Suen, J.Y.; Johnson, D.W.; Gobe, G.C.; Fairlie, D.P.; Vesey, D.A. Expression of protease activated receptor-2 is reduced in renal cell carcinoma biopsies and cell lines. PLoS ONE 2021, 16, e0248983. [Google Scholar] [CrossRef]
  35. Elieh Ali Komi, D.; Shafaghat, F.; Haidl, G. Significance of mast cells in spermatogenesis, implantation, pregnancy, and abortion: Cross talk and molecular mechanisms. Am J Reprod Immunol 2020, 83, e13228. [Google Scholar] [CrossRef]
  36. Ammendola, M.; Sacco, R.; Sammarco, G.; Luposella, M.; Patruno, R.; Gadaleta, C.D.; Sarro, G.D.; Ranieri, G. Mast Cell-Targeted Strategies in Cancer Therapy. Transfus Med Hemother 2016, 43, 109–113. [Google Scholar] [CrossRef]
  37. Singh, J.; Shah, R.; Singh, D. Targeting mast cells: Uncovering prolific therapeutic role in myriad diseases. Int Immunopharmacol 2016, 40, 362–384. [Google Scholar] [CrossRef]
  38. Vitte, J. Human mast cell tryptase in biology and medicine. Mol Immunol 2015, 63, 18–24. [Google Scholar] [CrossRef]
  39. Caughey, G.H. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 2007, 217, 141–154. [Google Scholar] [CrossRef]
  40. Yu, M.; Tsai, M.; Tam, S.Y.; Jones, C.; Zehnder, J.; Galli, S.J. Mast cells can promote the development of multiple features of chronic asthma in mice. J Clin Invest 2006, 116, 1633–1641. [Google Scholar] [CrossRef]
  41. Krystel-Whittemore, M.; Dileepan, K.N.; Wood, J.G. Mast Cell: A Multi-Functional Master Cell. Front Immunol 2015, 6, 620. [Google Scholar] [CrossRef] [PubMed]
  42. Collier, I.E.; Legant, W.; Marmer, B.; Lubman, O.; Saffarian, S.; Wakatsuki, T.; Elson, E.; Goldberg, G.I. Diffusion of MMPs on the surface of collagen fibrils: The mobile cell surface-collagen substratum interface. PLoS ONE 2011, 6, e24029. [Google Scholar] [CrossRef]
  43. Elahirad, S.; Elieh Ali Komi, D.; Kiani, A.; Mohammadi-Noori, E.; Vaisi-Raygani, A.; Mozafari, H.; Bahrehmand, F.; Saidi, M.; Toupchi-Khosroshahi, V.; Salehi, N. Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Polymorphisms, Their Serum Levels, and Activities with Coronary Artery Calcification (CAC) in an Iranian Population. Cardiovasc Toxicol 2022, 22, 118–129. [Google Scholar] [CrossRef] [PubMed]
  44. Guo, Z.; Zhou, G.; Hu, W. Carcinogenesis induced by space radiation: A systematic review. Neoplasia 2022, 32, 100828. [Google Scholar] [CrossRef]
  45. Barr, Y.R.; Bacal, K.; Jones, J.A.; Hamilton, D.R. Breast cancer and spaceflight: Risk and management. Aviat Space Environ Med 2007, 78, A26–A37. [Google Scholar] [PubMed]
  46. Komi, D.E.A.; Khomtchouk, K.; Santa Maria, P.L. A Review of the Contribution of Mast Cells in Wound Healing: Involved Molecular and Cellular Mechanisms. Clin Rev Allergy Immunol 2020, 58, 298–312. [Google Scholar] [CrossRef] [PubMed]
  47. Afonin, B.V. The hemodynamic mechanism determining the emergence of a hypersecretory state of the stomach in microgravity conditions. Aviakosmicheskaya i ekologicheskaya meditsina 2013, 47, 10–11. [Google Scholar]
  48. Molinari, J.F.; Scuri, M.; Moore, W.R.; Clark, J.; Tanaka, R.; Abraham, W.M. Inhaled tryptase causes bronchoconstriction in sheep via histamine release. Am J Respir Crit Care Med 1996, 154, 649–653. [Google Scholar] [CrossRef]
  49. Thomas, V.A.; Wheeless, C.J.; Stack, M.S.; Johnson, D.A. Human mast cell tryptase fibrinogenolysis: Kinetics, anticoagulation mechanism, and cell adhesion disruption. Biochemistry 1998, 37, 2291–2298. [Google Scholar] [CrossRef]
  50. Atiakshin, D.A.; Bykov, E.G.; Il’in, E.A.; Pashkov, A.N. [Tissue-specific reaction of the mucous coat of herbals’ small gut under the influence of spaceflight factors on board biosat “Foton M3”]. Aviakosm Ekolog Med 2011, 45, 25–30. [Google Scholar]
  51. Morey-Holton, E.; Globus, R.K.; Kaplansky, A.; Durnova, G. The hindlimb unloading rat model: Literature overview, technique update and comparison with space flight data. Adv Space Biol Med 2005, 10, 7–40. [Google Scholar] [CrossRef]
  52. Buchwalow, I.B.; Böcker, W. Immunohistochemistry: Basics and methods; Springer Science & Business Media, 2010. [Google Scholar]
  53. Naji-Haddadi, S.; Elieh-Ali-Komi, D.; Aghayan, S.; Asghari, R.; Rasouli, J. Investigation of p16 protein expression and its association with histopathologic parameters in breast cancer. Mol Biol Res Commun 2021, 10, 165–170. [Google Scholar] [CrossRef]
  54. Omelyanenko, N.P.; Slutsky, L.I. Connective tissue (histophysiology and biochemistry); RAS and RAMS ed.; Mironov, S.P., Ed.; Izvestia Publishing House: Moscow, 2009; Volume 1. [Google Scholar]
Table 1. The content of tryptase- and chymase-positive MCs in the digestive organs of Mongolian gerbils (detected by immunohistochemical staining, per a field of vision).
Table 1. The content of tryptase- and chymase-positive MCs in the digestive organs of Mongolian gerbils (detected by immunohistochemical staining, per a field of vision).
Groups of animals MC subpopulation MC identification technique
Tryptase MCs Chymase MCs
Jejunum Stomach Liver Jejunum Stomach Liver
Experiment “Rodentsiya”
VC MSMC 39.6 ± 2.2 4.4 ± 0.3 3.2 ± 0.4 2.6 ± 0.4 Single Single
CSMC 2.5 ± 0.2 1.5 ± 0.2 Single 1.1 ± 0.2
SE MSMC 42.4 ± 2.8 4.3 ± 0.3 2.9 ± 0.2 2.8 ± 0.2 Single Single
CSMC 2.8 ± 0.3 1.4 ± 0.1 0.4 ± 0.0* 1.3 ± 0.1
SF MSMC 28.6 ± 1.1 2.6 ± 0.2 2.2 ± 0.2 7.8 ± 0.8 1.2 ± 0.1 1.8 ± 0.2
CSMC 2.1 ± 0.2 1.4 ± 0.2 2.2 ± 0.1 1.5 ± 0.1
Simulated physiological effects of 12-day weightlessness
VC MSMC 36.8 ± 2.7 4.1 ± 0.7 2.9 ± 0.3 2.9 ± 0.2 Single Single
CSMC 2.4 ± 0.3 1.4 ± 0.1 Single 1.2 ± 0.1
AnOrtSusp MSMC 33.4 ± 2.5 4.8 ± 0.4 3.8 ± 0.2* 3.6 ± 0.1* 0.3 ± 0.1* 0.8 ± 0.2*
CSMC 2.9 ± 0.3 1.7 ± 0.2 0.5 ± 0.1* 1.4 ± 0.1
Notes and abbreviations: VC—vivarium control; SE—synchronous experiment; SF—space flight; AnOrtSusp—antiorthostatic suspension; MSMC—mucosal subpopulation of mast cells; CSMC—connective tissue subpopulation of mast cells; *—p < 0.05 compared to vivarium control, **—p < 0.05 compared to synchronous experiment.
Table 2. Protease profile of mast cells in the digestive organs of Mongolian gerbils (detected by multiple immunolabeling, fluorescence microscopy, %).
Table 2. Protease profile of mast cells in the digestive organs of Mongolian gerbils (detected by multiple immunolabeling, fluorescence microscopy, %).
Groups of animals Organs MC mucosal subpopulation MC connective tissue subpopulation
MCTRY MCCHYM MCTRY+CHYM MCTRY MCCHYM MCTRY+CHYM
Experiment “Rodentsiya”
VC Jejunum 89.8 ± 3.1 6.1 ± 0.2 4.1 ± 0.2 94.3 ± 3.3 3.8 ± 0.2 1.9 ± 0.1
Stomach 91.1 ± 2.3 3.2 ± 0.2 5.7 ± 0.4 45.4 ± 2.8 27.3 ± 3.4 27.3 ± 3.4
Liver1 - - - 97.2 ± 2.4 0.9 ± 0.2 1.9 ± 0.1
SE Jejunum 90.6 ± 4.4 6.0 ± 0.4 3.4 ± 0.3 84.8 ± 4.2* 12.1 ± 1.1* 3.1 ± 0.2*
Stomach 89.4 ± 4.2 3.8 ± 0.3 6.8 ± 0.3 43.4 ± 4.2 26.3 ± 2.3 30.3 ± 2.5
Liver1 - - - 97.1 ± 3.3 0.7 ± 0.1 2.2 ± 0.3
SF Jejunum 65.7 ± 4.5*.** 17.9 ± 1.1*.** 16.4 ± 1.2*.** 33.3 ± 2.8*.** 34.9 ± 3.4*.** 31.8 ± 2.5*.**
Stomach 25.4 ± 0.2*.** 28.4 ± 1.9*.** 46.2 ± 3.3*.** 24.2 ± 2.2*.** 36.7 ± 3.6*.** 39.1 ± 3.9*.**
Liver1 - - - 21.3 ± 2.8*.** 22.4 ± 1.2*.** 56.3 ± 1.8*.**
Simulated physiological effects of 12-day weightlessness
VC Jejunum 90.1 ± 3.1 5.4 ± 0.3 4.5 ± 0.5 93.4 ± 3.2 4.2 ± 0.3 2.4 ± 0.2
Stomach 87.6 ± 4.2 6.2 ± 0.5 6.2 ± 0.4 43.2 ± 3.1 25.7 ± 2.7 31.1 ± 1.4
Liver1 - - - 96.5 ± 2.9 1.5 ± 0.1 2.0 ± 0.3
AnOrtSusp Jejunum 79.5 ± 3.2* 8.3 ± 0.4* 12.2 ± 0.9* 81.4 ± 4.5* 9.2 ± 0.6* 9.4 ± 0.5*
Stomach 65.0 ± 3.5* 12.6 ± 1.1* 22.4 ± 2.0* 26.2 ± 1.9* 35.6 ± 3.1* 38.2 ± 2.2*
Liver1 - - - 76.3 ± 3.8* 5.4 ± 0.6* 18.3 ± 1.1*
Notes and abbreviation: VC—vivarium control; SE—synchronous experiment; SF—space flight; AnOrtSusp—antiorthostatic suspension; MCTRY—tryptase-positive mast cells; MCCHYM—chymase-positive mast cells; MCTRY+CHYM—mast cells with simultaneous tryptase and chymase expression; *—p < 0.05 compared to vivarium control, **—p < 0.05 compared to synchronous experiment. 1—Hepatic MCs are represented by a connective tissue subpopulation.
Table 3. Primary Antibodies used in the study.
Table 3. Primary Antibodies used in the study.
Antibodies Host Catalogue Nr. Dilution Source
Tryptase Mouse monoclonal Ab #ab2378 1:2000 AbCam, United Kingdom
Mast cell Chymase/CHYMASE Antibody, Biotin Conjugated Rabbit Polyclonal Ab #bs-2353R-Biotin 1:500 Bioss
Table 4. Secondary antibodies and other reagents.
Table 4. Secondary antibodies and other reagents.
Antibodies and Other Reagents Source Dilution Label
Goat anti-mouse IgG (#115-007-003) Jackson ImmunoResearh 1:13 w/o
Cy3-conjugated AffinPure Goat Anti Mouse IgG (#115-165-166) Jackson ImmunoResearh 10 мг/1 мл PBS Cy3
Streptavidin (# S11223) Invitrogen™ 2 mg/mL solution Alexa Fluor 488
AmpliStain™ anti-Mouse 1-Step HRP (#AS-M1-HRP) SDT GmbH, Baesweiler, Germany ready-to-use HRP
AmpliStain™ anti-Rabbit 1-Step HRP (#AS-R1-HRP) SDT GmbH, Baesweiler, Germany ready-to-use HRP
4′,6-diamidino-2-phenylindole (DAPI, #D9542-5MG) Sigma, Hamburg, Germany 5 µg/mL w/o
VECTASHIELD®® Mounting Medium (#H-1000) Vector Laboratories, Burlingame, CA, USA ready-to-use w/o
DAB Peroxidase Substrat Kit (#SK-4100) Vector Laboratories, Burlingame, CA, USA ready-to-use DAB
Mayer’s hematoxylin (#MHS128) Sigma-Aldrich ready-to-use w/o
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Downloads

92

Views

42

Comments

0

Subscription

Notify me about updates to this article or when a peer-reviewed version is published.

Email

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

© 2025 MDPI (Basel, Switzerland) unless otherwise stated